Advertisement
Screener

LEXMARK INTERNATIONAL INC /KY/ Spending and interest coverage

LEXMARK INTERNATIONAL INC /KY/ Spending and interest coverage

  • R&D / revenue · 12 months: Value 9.06%; Formula and calculation Research and development expense / revenue. Period ending 2016-09-30..
  • Stock-based compensation / revenue · 12 months: Value 1.44%; Formula and calculation Share-based compensation / revenue. Period ending 2016-09-30..
  • Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..

Spending and interest coverage

Overview →

Financial period ending 2016-09-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
R&D / revenue · 12 months9.06%Research and development expense / revenue. Period ending 2016-09-30.

$315.30M ÷ $3.48B × 100 ≈ 9.06%

Stock-based compensation / revenue · 12 months1.44%Share-based compensation / revenue. Period ending 2016-09-30.

$50.10M ÷ $3.48B × 100 ≈ 1.44%

Interest coverage · 12 months(m)Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Research and development spending315.30M USDResearch and Development Expense
Revenue3.48B USD
Stock-based compensation50.10M USDShare-based Payment Arrangement, Noncash Expense
Operating income-2.70M USDOperating Income (Loss)
Interest expense · reported / estimated(m)Interest Expense · Estimated expense assumptions

Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingResearch and development spending (USD)Revenue (USD)Stock-based compensation (USD)Operating income (USD)Interest expense · reported / estimated (USD)R&D / revenueSBC / revenueInterest coverageInterest expense basis
2016-09-30$315.30M$3.48B$50.10M$-2.70M(m)9.06%1.44%(m)(m)
2016-06-30$328.50M$3.49B$50.20M$-60.10M(m)9.42%1.44%(m)(m)
2016-03-31$338.20M$3.51B$48.90M$-105.20M(m)9.65%1.39%(m)(m)
2015-12-31$332.20M$3.55B$37.30M$-24.50M$46.50M9.35%1.05%-0.53×Reported
2015-09-30$352.20M$3.61B$32.70M$-23.10M(m)9.77%0.91%(m)(m)
2015-06-30$357.70M$3.67B$27.60M$52.90M(m)9.74%0.75%(m)(m)
2015-03-31$353.20M$3.68B$23.90M$137.50M(m)9.59%0.65%(m)(m)
2014-12-31$354.50M$3.71B$27.70M$149.20M$42.50M9.55%0.75%3.51×Reported
2014-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-03-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-12-31(m)$3.67B(m)$409.30M(m)(m)(m)(m)(m)
2013-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-03-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-12-31(m)$3.80B(m)$191.50M(m)(m)(m)(m)(m)
2012-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-03-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-12-31(m)$4.17B(m)$442.90M(m)(m)(m)(m)(m)
2011-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-03-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2010-12-31(m)$4.20B(m)$447.00M(m)(m)(m)(m)(m)
2010-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2010-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2010-03-31(m)(m)(m)(m)(m)(m)(m)(m)(m)
2009-12-31$375.30M$3.88B$20.40M$216.10M$39.30M9.67%0.53%5.50×Reported
2009-09-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2009-06-30(m)(m)(m)(m)(m)(m)(m)(m)(m)
2008-12-31$423.30M$4.53B$32.70M$277.20M(m)9.35%0.72%(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.